AtriCure, Inc. (ATRC) — Analysis Summary
AtriCure, Inc. (ATRC) has a market cap of $1.76B with year-over-year revenue growth of +14.9%. Net margin stands at -2.1%. The stock trades at a P/E ratio of -383.7.
Key Takeaways
- Revenue changed +14.9% year-over-year
- Net margin of -2.1%
- P/E ratio of -383.7
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, ATRC posted revenue growth of +14.9% and trades at a P/E of -383.7.
AtriCure, Inc. (ATRC)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.7x — highly leveraged, potential refinancing risk
Interest coverage at -0.5x — earnings do not cover interest payments
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
1,350
Headquarters
MASON, OH
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.